AIM ImmunoTech (NYSE:AIM) Price Target Cut to $4.50 by Analysts at Ascendiant Capital Markets

AIM ImmunoTech (NYSE:AIM) had its price objective trimmed by Ascendiant Capital Markets from $5.00 to $4.50 in a report issued on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, Maxim Group cut their price objective on shares of AIM ImmunoTech from $2.00 to $1.00 and set a “buy” rating on the stock in a research note on Tuesday, October 22nd.

AIM ImmunoTech Stock Performance

Shares of AIM ImmunoTech stock opened at $0.22 on Tuesday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 0.05. AIM ImmunoTech has a 12-month low of $0.16 and a 12-month high of $0.62. The firm has a market capitalization of $13.90 million, a price-to-earnings ratio of -0.48 and a beta of -0.36. The firm’s 50 day simple moving average is $0.24 and its two-hundred day simple moving average is $0.31.

Institutional Trading of AIM ImmunoTech

An institutional investor recently bought a new position in AIM ImmunoTech stock. Armistice Capital LLC purchased a new position in shares of AIM ImmunoTech Inc. (NYSE:AIM) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned approximately 7.92% of AIM ImmunoTech as of its most recent filing with the Securities and Exchange Commission (SEC). 12.02% of the stock is currently owned by institutional investors.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).